Tillotts Pharma announces the launch of Octasa 1600 mg Tablets in Canada
The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
Extends patent protection for Microbion's proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Abbas will closely partner with CBC's business teams to identify, assess, and pursue investment opportunities and strategic acquisitions
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
The upcoming portfolio of respiratory products aims to provide effective solutions for a range of respiratory conditions
Getinge has a strong market share in India within several product segments
Pre-filled pens containing a combination of insulin glargine 100 Units/mL and lixisenatide for once-daily dosing
Subscribe To Our Newsletter & Stay Updated